当前位置: X-MOL 学术Genes Dev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
Genes & Development ( IF 7.5 ) Pub Date : 2022-03-01 , DOI: 10.1101/gad.349368.122
Jan Philipp Bewersdorf 1 , Omar Abdel-Wahab 1, 2
Affiliation  

Despite FDA approval of nine new drugs for patients with acute myeloid leukemia (AML) in the United States over the last 4 years, AML remains a major area of unmet medical need among hematologic malignancies. In this review, we discuss the development of promising new molecular targeted approaches for AML, including menin inhibition, novel IDH1/2 inhibitors, and preclinical means to target TET2, ASXL1, and RNA splicing factor mutations. In addition, we review progress in immune targeting of AML through anti-CD47, anti-SIRPα, and anti-TIM-3 antibodies; bispecific and trispecific antibodies; and new cellular therapies in development for AML.

中文翻译:


将急性髓系白血病发病机制的最新进展转化为临床



尽管 FDA 在过去 4 年里批准了美国急性髓系白血病 (AML) 患者的九种新药,但 AML 仍然是血液系统恶性肿瘤中医疗需求未得到满足的一个主要领域。在这篇综述中,我们讨论了有前景的 AML 新型分子靶向方法的开发,包括 menin 抑制、新型 IDH1/2 抑制剂以及针对TET2ASXL1和 RNA 剪接因子突变的临床前方法。此外,我们回顾了通过抗CD47、抗SIRPα和抗TIM-3抗体免疫靶向AML的进展;双特异性和三特异性抗体;以及正在开发的针对 AML 的新细胞疗法。
更新日期:2022-03-01
down
wechat
bug